Overview

Poland has the largest Pharmaceutical market in Central and Eastern Europe and a structured healthcare system boasting good market opportunities for aspiring medicinal product manufacturers. For compliant market access, manufacturers must register their medicinal products with Chief Pharmaceutical Inspectorate of Poland. As per the Directive 2001/83/EC, any new medicinal product shall be registered through a Marketing Authorization Application (MAA) following certain procedures:  

  • Article 8(3) for New Chemical Entity (NCE) 
  • Article 10 for generic, hybrid and similar biological medicinal products  

Further, the Market Authorization Holder (MAH) has to meet all the requirements listed out by the European Union (EU) and European Economic Area (EEA) considering the UK as a 3rd country post March 30, 2019.

The tough clinical trial regulations of Poland may challenge the submissions adequacy and approvals. Right from choosing dependant local representative, adapting to suitable submission pathway is crucial the product’s acceptance into the country. Enabling manufacturers understand the best of market and Regulatory information, Freyr supports applicants in accurate dossier compilation, submission and lifecycle management along with reliable legal representation services.

Freyr Expertise 

  • Initial submissions (MAAs) via various procedures- National, Mutual Recognition Procedure (MRP), Decentralized Procedure (DCP) and Centralized Procedure (CP) for innovator, hybrid and generic products 
  • Regulatory consultation and strategic support on submission roadmaps, and procedures 
  • Pre-submission administrative activities such as interaction with Health Authorities (HAs), slot booking for submissions, selection of the RMS and CMS, request to HA to work as RMS 
  • Evaluation of the product and source data from R&D and manufacturing site (executed data) for the EU-specific Regulatory and submission requirements 
  • Compilation and submission of the dossiers to HAs in electronic common technical document (eCTD) format in line with Chief Pharmaceutical Inspectorate of Poland requirements 
  • Consultation during developments and manufacturing of the medicinal products 
  • Initial submissions for APIs - ASMF/ CEP submissions  
  • Qualified Person (QP), Qualified Person for Pharmacovigilance (QPPV) in the EU 
  • Post-approval changes submissions with strategies and compilation/ submission for:   
    • Marketing authorization holder (MAH) transfers 
    • Post-approval quality change like-  
      • Change in manufacturing site, addition/deletion of the site, Batch size change, changes in manufacturing changes, administrative and labeling changes 
    • Monograph updates i.e. compliance to European pharmacopoeia 
    • Changes in container closure system 
    • Change in primary packaging material supplier 
    • Shelf life extension/reduction 
    • Addition of new supplier for active substance 
    • Inclusion of additional source for starting material for drug substance 
  • Impact analysis of Brexit and submission of the relevant changes to HA(s) like- change in Reference Member State (RMS), changes to MAH, addition/ replacement of the batch release and testing sites, changes to the QP, QPPV and Pharmacovigilance system master file (PSMF) (Article 57 notification) 
  • Life cycle maintenance by submission of renewal applications 
  • Support in handling Chief Pharmaceutical Inspectorate of Poland’s deficiencies with Regulatory strategy and preparation and submission of the response